On reducing the risk of vaccine-associated paralytic poliomyelitis in the global transition from oral to inactivated poliovirus vaccine

The Lancet
https://www.thelancet.com/journals/lancet/issue/current
Aug 18, 2018 Volume 392 Number 10147 p531-612

Viewpoint
On reducing the risk of vaccine-associated paralytic poliomyelitis in the global transition from oral to inactivated poliovirus vaccine
Xiangdong Peng, Xiaojiang Hu, Miguel A Salazar
Owing to the concerted efforts of countries worldwide, the incidence of paralytic poliomyelitis due to wild poliovirus infection has been reduced to its lowest on record. Wild poliovirus type 2 has not been detected since 1999 and was certified to have been eradicated in 2015.  No case of paralytic poliomyelitis caused by wild poliovirus type 3 has been reported since 2012, and all cases detected since 2013 have been due to wild poliovirus type 1.  In 2016, only 37 cases of paralytic poliomyelitis caused by wild poliovirus infection were reported, and that number decreased to 22 in 2017. Global eradication of wild poliovirus—the long-awaited outcome of decades of effort—is finally in sight.